Correction to: Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L

Ariel Zisman; Terry Dex; Michelle Roberts; Aramesh Saremi; Jason Chao; Vanita R Aroda

doi:10.1007/s13300-018-0544-8

Correction to: Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L

Diabetes Ther. 2019 Feb;10(1):327. doi: 10.1007/s13300-018-0544-8.

Authors

Ariel Zisman¹, Terry Dex², Michelle Roberts², Aramesh Saremi², Jason Chao³, Vanita R Aroda⁴

Affiliations

¹ Endocrine Center of Aventura, Miami, FL, USA. [email protected].
² Sanofi US, Inc, Bridgewater, NJ, USA.
³ Xinyi, Inc, Bridgewater, NJ, USA.
⁴ Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Abstract

In the original publication, the text in abstract section under the 'Results' section is incorrectly published as 'higher proportion of patients reached a BeAM value < 55 mg/dL.

Publication types

Published Erratum